Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > B7-1 > CD0-C52H3

Cynomolgus / Rhesus macaque B7-1 / CD80 Protein, His Tag (MALS verified)

Order Now

  • Synonym
    CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7
  • Source
    Cynomolgus / Rhesus macaque B7-1, His Tag (CD0-C52H3) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # G7NXN7). In the region Val 35 - Asn 242, the AA sequence of Cynomolgus and Rhesus macaque B7-1 are homologus.
    Predicted N-terminus: Val 35
  • Molecular Characterization
    B7-1 Structure

    This protein carries a polyhistidine tag at the C-terminus

    The protein has a calculated MW of 25.8 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
B7-1 SDS-PAGE

Cynomolgus / Rhesus macaque B7-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
B7-1 MALS images

The purity of Cynomolgus / Rhesus macaque B7-1, His Tag (Cat. No. CD0-C52H3) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Bioactivity-ELISA
 B7-1 ELISA

Immobilized Cynomolgus / Rhesus macaque CTLA-4, Fc Tag (Cat. No. CT4-C5256) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-1, His Tag (Cat. No. CD0-C52H3) with a linear range of 10-156 ng/mL (QC tested).

 B7-1 ELISA

Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-1, His Tag (Cat. No. CD0-C52H3) with a linear range of 10-156 ng/mL (Routinely tested).

  • Background
    B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.
    B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $260.00

Price(USD) : $1940.00

Recommended Products
Monoclonal Anti-His Tag Antibody

Price(USD) : $240.00

Price(USD) : $1580.00

HRP conjugated Anti-His Tag Antibody

Price(USD) : $250.00

Price(USD) : $1680.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:2 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message